7,278
Total Publications
223,396
Total Citations
Top Researchers
- James Chih‐Hsin Yang 109,782 citations • 1220 papers
- Ken Chen 99,904 citations • 1058 papers
- Hai Hu 91,562 citations • 398 papers
- Pan‐Chyr Yang 63,260 citations • 1362 papers
- Xuetao Cao 53,627 citations • 843 papers
- Jian Wang 48,828 citations • 1339 papers
- S. Xiao 43,665 citations • 225 papers
- H. J. Yang 43,048 citations • 2884 papers
- Jian Li 42,813 citations • 1133 papers
- Peng Huang 42,423 citations • 522 papers
Most Cited Papers
- NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential 2020 • 958 citations
- A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria 2010 • 844 citations
- Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma 2021 • 777 citations
- Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study 2023 • 623 citations
- Exosomes Derived from Hypoxic Oral Squamous Cell Carcinoma Cells Deliver miR-21 to Normoxic Cells to Elicit a Prometastatic Phenotype 2016 • 560 citations
- Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source 2020 • 557 citations
- Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial 2022 • 547 citations
- Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment 2022 • 530 citations
- Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study 2017 • 526 citations
- NF‐κB signaling in inflammation and cancer 2021 • 498 citations